GET DAILY SIGNALSUnited Therapeutics (UTHR) Posts Record Revenue as Tyvaso Franchise Hits New High
Key Takeaways
- United Therapeutics reported third quarter 2026 revenue of $832.5 million, up 4.1% from $799.5 million a year earlier and ahead of analyst consensus estimates.
- Diluted earnings per share (EPS) came in at $5.71, below consensus expectations and down from $7.16 in the prior-year quarter, reflecting higher expenses and a larger tax bill.
- The Tyvaso franchise reached a record $504 million in quarterly sales, led by Tyvaso DPI (dry powder inhaler) growth of 13%.
- Net income declined to $258.6 million from $338.7 million a year earlier, pressured by higher research and development spending tied to acquisitions and pipeline programs.
- Shares rose sharply in early trading after the report as investors focused on record revenue and a favorable settlement with Liquidia that protects the PH-ILD market.
- For more detail, explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated UTHR pages.
- You can also explore Trending AI Robots to see how AI-driven trading strategies are tracking stocks like UTHR.
Earnings Context and Why It Matters
United Therapeutics is a biotechnology company best known for its treprostinil-based therapies for pulmonary arterial hypertension (PAH), a serious condition involving high blood pressure in the arteries of the lungs. The company has been broadening its reach beyond PAH into pulmonary fibrosis and next-generation organ manufacturing, making each quarterly report a checkpoint on both commercial momentum and pipeline execution. This particular report arrived with investors watching two things closely: whether the Tyvaso franchise could re-accelerate growth, and whether rising development costs would weigh on profitability. A late-October legal settlement with Liquidia also added a strategic dimension, potentially clearing a path for Tyvaso to defend its position in PH-ILD.
Reported Results
United Therapeutics reported third quarter 2026 total revenue of $832.5 million, a 4.1% increase from $799.5 million in the same period last year. The top line exceeded analyst consensus estimates, while diluted EPS of $5.71 fell short of expectations and was down from $7.16 a year earlier. Net income was $258.6 million, down from $338.7 million.
The Tyvaso franchise was the standout, generating a record $504 million, up 5% year over year. Tyvaso DPI contributed $378.5 million, up 13%, offsetting a 12% decline in nebulized Tyvaso to $125.3 million. Orenitram grew 11% to $145.0 million, and Unituxin rose 9% to $52.3 million, while Remodulin slipped 3% to $122.0 million. Profitability was pressured by higher research and development spending—including costs tied to the Thymmune acquisition—and an effective tax rate that climbed to 31% from 23% a year earlier. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
The market responded positively to the report despite the EPS shortfall, with UTHR shares climbing in early trading as investors emphasized the record revenue performance and the improving competitive backdrop. The settlement with Liquidia was a key sentiment driver: management said the agreement removes PH-ILD from the competing YUTREPIA label and restricts promotion into that indication, reducing near-term branded competition for Tyvaso. Investors also appeared to reward evidence of re-accelerating demand, including management's disclosure of more than 1,000 product referrals in October, the highest monthly total in company history. The profit decline, driven largely by elevated research and development spending and a higher tax rate, was generally viewed as investment for future growth rather than an operational deterioration.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching several pipeline milestones that could reshape the company's revenue base. The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application for nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF), with a target decision date of April 26, 2027. A separate New Drug Application for ralinepag, a once-daily oral therapy for PAH, has a decision date of June 24, 2027.
These regulatory events sit alongside the TETON clinical program, which generated strong data in pulmonary fibrosis, and the broader ambition to expand into larger patient populations across IPF, progressive pulmonary fibrosis, and PH-COPD. At the same time, investors should monitor the cost trajectory that pressured this quarter's earnings. Rising research and development spending and a higher effective tax rate may continue to weigh on near-term profitability even as revenue grows.
Capital allocation is another factor to follow. United Therapeutics completed a $2.0 billion share repurchase program and authorized a new $2.0 billion buyback in October 2026, signaling confidence in its cash position and long-term outlook. Finally, competitive dynamics in PAH and PH-ILD remain important, as does the company's ability to sustain the referral momentum it reported entering the fourth quarter. These factors, rather than a single quarterly EPS figure, will likely shape how investors assess UTHR's trajectory over the coming year.
AI Tools in My Research Workflow
When evaluating results like these, I often rely on Tickeron’s AI Screener to quickly compare UTHR against peers on fundamentals, technical signals, and sector trends. It helps me spot patterns across the biotech space without spending hours on manual screens. The tool has become a regular part of how I refine watchlists and confirm ideas before digging deeper into filings or forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UTHR in upward trend: price rose above 50-day moving average on September 30, 2026
UTHR moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend. In 27 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on UTHR as a result. In 64 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for UTHR just turned positive on September 30, 2026. Looking at past instances where UTHR's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.
The 10-day moving average for UTHR crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Following a +2.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTHR advanced for three days, in 221 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 186 of 266 cases where UTHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
UTHR broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. UTHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.078) is normal, around the industry mean (7.659). P/E Ratio (20.129) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (2.205) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (7.418) is also within normal values, averaging (181.047).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement